A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

NCT02168530 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: placebo
DRUG: vismodegib

Sponsor

Hoffmann-La Roche